Dr. Arend on Niraparib With Bevacizumab in Ovarian Cancer

Rebecca C. Arend, MD
Published: Wednesday, Nov 30, -0001



Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the combination of niraparib (Zejula) with bevacizumab (Avastin) for the treatment of patients with ovarian cancer.

There have been previous trials that have looked at niraparib and bevacizumab in the platinum-resistant setting, including a poster out of the 2017 ESMO Congress. That trial is still ongoing, however there are physicians who use that combination off-label, but it is currently only available in trials, explains Arend. However, niraparib and bevacizumab are both FDA-approved drugs.

Arend says that someone who is going to try those drugs should do it on a clinical trial so that we can organize our data and outcomes for those combinations. There are some trials with some encouraging results, but nothing final yet.
 


Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the combination of niraparib (Zejula) with bevacizumab (Avastin) for the treatment of patients with ovarian cancer.

There have been previous trials that have looked at niraparib and bevacizumab in the platinum-resistant setting, including a poster out of the 2017 ESMO Congress. That trial is still ongoing, however there are physicians who use that combination off-label, but it is currently only available in trials, explains Arend. However, niraparib and bevacizumab are both FDA-approved drugs.

Arend says that someone who is going to try those drugs should do it on a clinical trial so that we can organize our data and outcomes for those combinations. There are some trials with some encouraging results, but nothing final yet.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x